The 10-second takeaway
For the quarter ended March 31 (Q1), Antares Pharma crushed expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share improved to zero.
Margins increased across the board.
Antares Pharma reported revenue of $6.9 million. The three analysts polled by S&P Capital IQ looked for a top line of $4.4 million on the same basis. GAAP reported sales were 92% higher than the prior-year quarter's $3.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.00. The one earnings estimate compiled by S&P Capital IQ forecast -$0.02 per share. GAAP EPS contracted to zero from the prior-year quarter's -$0.02.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 71.0%, 1,170 basis points better than the prior-year quarter. Operating margin was -1.4%, 3,810 basis points better than the prior-year quarter. Net margin was -1.1%, 3,760 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $3.6 million. On the bottom line, the average EPS estimate is -$0.02.
Next year's average estimate for revenue is $26.1 million. The average EPS estimate is -$0.03.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 171 members out of 183 rating the stock outperform, and 12 members rating it underperform. Among 20 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give Antares Pharma a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $3.65.
Over the decades, small-cap stocks like Antares Pharma have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Antares Pharma to My Watchlist.